iRHOM2 takes control of rheumatoid arthritis

Journal of Clinical Investigation

Volumn 123, Issue 2, 2013, Pages 560-562

  Lichtenthaler, Stefan F ^a,b,c  

^a GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c Germany 3 Munich Cluster for Systems Neurology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C5A RECEPTOR; FC RECEPTOR; IRHOM 2; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; UNCLASSIFIED DRUG;

BONE MARROW CELL; CHONDROPATHY; ENZYME ACTIVITY; FIBROBLAST; IMMUNOCOMPETENT CELL; JOINT SWELLING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS;

ANIMALS; ARTHRITIS, EXPERIMENTAL; CARRIER PROTEINS; HUMANS;

EID: 84873345461     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI67548     Document Type: Review

References (17)

1. Zettl M, Adrain C, Strisovsky K, Lastun V, Freeman M. Rhomboid family pseudoproteases use the ER quality control machinery to regulate intercellular signaling. Cell. 2011;145(1):79-91.
2. Adrain C, Zettl M, Christova Y, Taylor N, Freeman M. Tumor necrosis factor signaling requires iRhom2 to promote trafficking and activation of TACE. Science. 2012;335(6065):225-228.
3. McIlwain DR, et al. iRhom2 regulation of TACE controls TNF-mediated protection against Listeria and responses to LPS. Science. 2012;335(6065):229- 232.
4. Siggs OM, et al. iRhom2 is required for the secretion of mouse TNFalpha. Blood. 2012;119(24):5769-5771.
5. Issuree PDA, et al. iRHOM2 is a critical pathogenic mediator of inflammatory arthritis. J Clin Invest. 2013;123(2):928-932.
6. Ditzel HJ. The K/BxN mouse: a model of human inflammatory arthritis. Trends Mol Med. 2004;10(1):40-45.
7. Ji H, et al. Critical roles for interleukin 1 and tumor necrosis factor alpha in antibody-induced arthritis. J Exp Med. 2002;196(1):77-85.
8. Ji H, et al. Arthritis critically dependent on innate immune system players. Immunity. 2002;16(2):157-168.
9. Scheller J, Chalaris A, Garbers C, Rose-John S. ADAM17: a molecular switch to control inflammation and tissue regeneration. Trends Immunol. 2011;32(8):380-387.
10. Lichtenthaler SF, Haass C, Steiner H. Regulated intramembrane proteolysis - lessons from amyloid precursor protein processing. J Neurochem. 2011;117(5):779-796.
11. Peschon JJ, et al. An essential role for ectodomain shedding in mammalian development. Science. 1998;282(5392):1281-1284.
12. Blaydon DC, et al. Inflammatory skin and bowel disease linked to ADAM17 deletion. N Engl J Med. 2011;365(16):1502-1508.
13. Brambilla R, et al. Inhibition of soluble tumour necrosis factor is therapeutic in experimental autoimmune encephalomyelitis and promotes axon preservation and remyelination. Brain. 2011;134(pt 9):2736-2754.
14. Gregory AP, et al. TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. Nature. 2012;488(7412):508-511.
15. Moss ML, Sklair-Tavron L, Nudelman R. Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat Clin Pract Rheumatol. 2008;4(6):300-309.
16. Blaydon DC, et al. RHBDF2 mutations are associated with tylosis, a familial esophageal cancer syndrome. Am J Hum Genet. 2012;90(2):340-346.
17. Borgegard T, et al. Alzheimer's disease: presenilin 2-sparing gamma-secretase inhibition is a tolerable Ab peptide-lowering strategy. J Neurosci. 2012;32(48):17297-17305.